This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Glaucoma  • Dermatology  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Arch Ophthalmol. 2005;123:1609-1610.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Topical bimatoprost (Lumigan; Allergan Inc, Irvine, Calif) is a prostamide analog licensed in the United States (2001) and in the United Kingdom (2002) as a second-line treatment modality for glaucoma and ocular hypertension. Unlike with latanoprost, there is little published evidence for any periocular skin pigmentary effects associated with bimatoprost. We herein report 3 cases of bimatoprost-related periorbital skin hyperpigmentation along with a review of the literature and a comparison with published latanoprost effects.

Report of Cases

Case 1. A 76-year-old white woman with normal-tension glaucoma in the left eye had been treated with 0.25% timolol eyedrops twice daily for 6 years. She was otherwise well and was receiving no other medication. Because of progressive optic disc damage, her treatment was changed to 0.03% bimatoprost eyedrops nightly in the left eye only. When followed up 2 months later, she commented that the skin around the left eye had become darker, developing an unsightly . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION
Gavin D. Galloway, MRCOphth; Tom Eke, FRCOphth, MD; David C. Broadway, FRCOphth, MD

RELATED ARTICLE

Bimatoprost-Induced Periocular Skin Hyperpigmentation: Histopathological Study
Rashmi Kapur, Smajo Osmanovic, Sami Toyran, and Deepak P. Edward
Arch Ophthalmol. 2005;123(11):1541-1546.
ABSTRACT | FULL TEXT